| アブストラクト | OBJECTIVE: To compare treatment patterns, persistence and adherence between fixed-dose combinations (FDCs) and two-pill combinations (TPCs) of oral antidiabetic drug (OAD) classes in Japanese patients with type 2 diabetes mellitus (T2DM) using administrative claims databases (Japan Medical Data Center [JMDC] and Medical Data Vision [MDV]). METHODS: This was a retrospective, longitudinal cohort analysis conducted between 2011 and 2015, in patients with T2DM receiving OADs as FDC or TPC. Outcomes included prescribing patterns, treatment persistence and adherence. RESULTS: Data from 3474 and 3066 patients receiving FDCs, and 4325 and 5192 patients receiving TPCs from the JMDC and MDV databases, respectively, was extracted. The most common OAD combination received by over half of all patients was dipeptidyl peptidase-4 inhibitor (DPP-4i) + thiazolidinediones (TZDs) (64.1% [JMDC] and 70.5% [MDV]). Overall, 12-month persistence rates were higher in patients receiving FDCs compared with TPCs (70.4 vs. 66.2% [JMDC], 75.6 vs. 55.7% [MDV]). In the JMDC population receiving FDCs or TPCs, persistence rates were highest with DPP-4i schedules (67.5-83.5%). Median time to discontinuation was significantly longer with biguanide + TZD, and DPP-4i + TZD FDC schedules (p < .05) than TPC; adherence rates were >/=80% across all antidiabetic drug classes in both database populations. CONCLUSIONS: Persistence with and adherence to OADs in Japanese patients with T2DM were greater with FDCs than with TPCs, which may suggest increased patient satisfaction due to reduced treatment burden. Further studies are warranted to investigate the impact of adherence and persistence of FDCs of OADs on glycemic control. |
|---|
| ジャーナル名 | Current medical research and opinion |
|---|
| Pubmed追加日 | 2018/11/22 |
|---|
| 投稿者 | Nishimura, Rimei; Kato, Haruka; Kisanuki, Koichi; Oh, Akinori; Onishi, Yoshie; Guelfucci, Florent; Shimasaki, Yukio |
|---|
| 組織名 | a The Jikei University School of Medicine , Tokyo , Japan.;b Japan Medical Affairs , Takeda Pharmaceutical Company Limited , Tokyo , Japan.;c Creativ-Ceutical , Japan Operations , Tokyo , Japan.;d Creativ-Ceutical , Paris , France. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/30460858/ |
|---|
